Belgium HIV Therapeutics Market Analysis Report [2022-30]

Belgium HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Belgium HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Mylan Belgium, Ablynx, and UCB. The market is driven by government policies and initiatives for the management of HIV infections in the country. The HIV therapeutics market in Belgium is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10BEPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Vishwa Modhia

Buy Now

Belgium HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Belgium HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Belgium is a Western European country that borders the North Sea. France, Germany, Luxembourg, and the Netherlands are all neighbours. According to the most recent WHO data, the number of HIV/AIDS-related deaths in Belgium had reach 200 by 2020. Belgium ranks 139th in the world, with a death rate of 0.26 per 100,000 people. In 2021, the adult prevalence of HIV/AIDS in Belgium was 0.1%. In Belgium, HIV/AIDS is primarily concentrated among men who have sex with men and Sub-Saharan Africans.

The rate of new HIV diagnoses in Brussels is higher than in other regions, reflecting the fact that HIV infection is primarily a city problem. 98.2% had HIV care connections, 90.8% were in care, and 83.3% were on antiretroviral therapy. Belgium spent 11.1% of its GDP on healthcare in 2019.

Market Dynamics

Market Growth Drivers

The implementation of the Belgian government's National Strategic Plan on HIV in 2013 was a step toward reducing HIV/AIDS transmission. The Belgian monarchy also supported this plan, which had three main goals: preventing HIV/AIDS, providing HIV/AIDS testing and treatment, and providing care and support. When developing the plan, the government made certain that it would specifically target vulnerable groups such as migrants. HIV patients are doing well in terms of treatment.

Almost all participants (96%) are on HIV medication, have good adherence (96%) and have an undetectable viral load (89%). This means they can no longer spread HIV through sex. They are also very pleased with the care provided in HIV reference centres (90%). This demonstrates the patient's adherence and can boost the HIV therapeutics market in Belgium.

Market Restraints

Following a study, an organisation called BREACH (Belgian Research on AIDS and HIV Consortium) concluded that the undiagnosed HIV-infected population, which is estimated to be around 20%, was potentially the weakest link in efforts to combat the HIV/AIDS epidemic in Belgium. This was especially prevalent among migrants in Belgium, and it is a problem that must be addressed.

There is also a link between poverty and HIV/AIDS patients. According to research published in the Journal of the International AIDS Society on the link between AIDS and poverty, migration vulnerabilities such as economic hardship and barriers to HIV testing mean that non-citizens are more likely to become infected with HIV/AIDS. All these factors can discourage new players from entering the Belgium HIV therapeutics market.

Competitive Landscape

Key Players

UCB (BEL)
Ablynx (BEL)
Galapagos (BEL)
Mithra Pharmaceuticals (BEL)
Mylan Belgium (BEL)
Roche
AbbVie

Healthcare Regulations and Reimbursement Policies

The Federal Agency for Medicines and Health Products (FAMHP), which reports to the Belgian Ministry of Health, is the regulatory body in charge of approving HIV therapeutics. The FAMHP is in charge of evaluating the safety, efficacy, and quality of HIV medications as well as issuing marketing authorizations. The agency is also in charge of enforcing regulatory compliance and monitoring the safety and efficacy of drugs after they have been approved. HIV drugs in Belgium are governed by European Union (EU) regulations.

HIV therapeutics are reimbursed in Belgium through the national health insurance system, which is managed by the National Institute for Health and Disability Insurance (NIHDI). HIV therapeutics are included on the "positive list," which is a list of drugs and medical devices that are eligible for reimbursement. Patients with HIV can get medication reimbursement if they meet certain requirements, such as having a valid prescription from a licenced physician and being enrolled in the national health insurance programme.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.